Potent and Tumor specific: Arming Bacteria With Therapeutic Proteins

References

• Minchinton AI Tannock IF . Drug penetration in solid tumours. Nat. Rev. Cancer6 (8), 583–592 (2006).
   PubMed Web of Science ®Google Scholar
• St Jean AT Zhang M Forbes NS . Bacterial therapies: completing the cancer treatment toolbox. Curr. Opin. Biotechnol.19 (5), 511–517 (2008).
   PubMed Web of Science ®Google Scholar
• Jain RK . The next frontier of molecular medicine: delivery of therapeutics. Nat. Med.4 (6), 655–657 (1998).
   PubMed Web of Science ®Google Scholar
• Kasinskas RW Forbes NS . Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol. Bioeng.94 (4), 710–721 (2006).
   PubMed Web of Science ®Google Scholar
• Sznol M Lin SL Bermudes D Zheng LM King I . Use of preferentially replicating bacteria for the treatment of cancer. J. Clin. Invest.105 (8), 1027–1030 (2000).
   PubMed Web of Science ®Google Scholar
• Streilein JW . Unraveling immune privilege. Science270 (5239), 1158–1159 (1995).
   PubMed Web of Science ®Google Scholar
• Forbes NS Munn LL Fukumura D Jain RK . Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res.63 (17), 5188–5193 (2003).
   PubMed Web of Science ®Google Scholar
• Quispe-Tintaya W Chandra D Jahangir A et al. Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer. Proc. Natl Acad. Sci. USA110 (21), 8668–8673 (2013).
   PubMed Web of Science ®Google Scholar
• Toley BJ Forbes NS . Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. Integr. Biol.4 (2), 165–176 (2012).
   Google Scholar
• Zhang M Forbes NS . Trg-deficient Salmonella colonize quiescent tumor regions by exclusively penetrating or proliferating. J. Control Release199, 180–189 (2014).
   PubMed Web of Science ®Google Scholar
• Ganai S Arenas RB Sauer JP Bentley B Forbes NS . In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther.18 (7), 457–466 (2011).
   PubMed Web of Science ®Google Scholar
• Luo X Li ZJ Lin S et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol. Res.12 (11–12), 501–508 (2001).
   PubMed Web of Science ®Google Scholar
• Agrawal N Bettegowda C Cheong I et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl Acad. Sci. USA101 (42), 15172–15177 (2004).
   PubMed Web of Science ®Google Scholar
• Zhao M Yang M Ma HY et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res.66 (15), 7647–7652 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao M Geller J Ma H Yang M Penman S Hoffman RM . Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc. Natl Acad. Sci. USA104 (24), 10170–10174 (2007).
   PubMed Web of Science ®Google Scholar
• Lee CH Wu CL Tai YS Shiau AL . Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol. Ther.11 (5), 707–716 (2005).
   PubMed Web of Science ®Google Scholar
• Lee CH Hsieh JL Wu CL Hsu PY Shiau AL . T cell augments the antitumor activity of tumor-targeting Salmonella. Appl. Microbio. Biotechnol.90 (4), 1381–1388 (2011).
   PubMed Web of Science ®Google Scholar
• Toso JF Gill VJ Hwu P et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol.20 (1), 142–152 (2002).
   PubMed Web of Science ®Google Scholar
• Jiang SN Phan TX Nam TK et al. Inhibition of tumor growth and metastasis by a combination of escherichia coli-mediated cytolytic therapy and radiotherapy. Mol. Ther.18 (3), 635–642 (2010).
   PubMed Web of Science ®Google Scholar
• St Jean AT Swofford CA Brentzel ZJ Forbes NS . Bacterial delivery of Staphylococcus aureus alpha-hemolysin causes tumor regression and necrosis in murine tumors. Mol. Ther.22 (7), 1266–1274 (2013).
   Web of Science ®Google Scholar
• Swofford CA St Jean AT Panetli JT Brentzel ZJ Forbes NS . Identification of Staphylococcus aureus α-hemolysin as a protein drug that is secreted by anticancer bacteria and rapidly kills cancer cells. Biotechnol. Bioeng.111 (6), 1233–1245 (2013).
   Web of Science ®Google Scholar
• Zhang Y Xia L Zhang X Ding X Yan F Wu F . Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein. Appl. Environ. Microbiol.78 (21), 7603–7610 (2012).
   PubMed Web of Science ®Google Scholar
• Loeffler M Le'negrate G Krajewska M Reed JC . Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc. Natl. Acad. Sci. USA104, 12879–12883 (2007).
   PubMed Web of Science ®Google Scholar
• Loeffler M Le'negrate G Krajewska M Reed JC . Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol. Immunother.58 (5), 769–775 (2009).
   PubMed Web of Science ®Google Scholar
• Loeffler M Le'negrate G Krajewska M Reed JC . IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther.15 (12), 787–794 (2008).
   PubMed Web of Science ®Google Scholar
• Al-Ramadi BK Fernandez-Cabezudo MJ El-Hasasna H Al-Salam S Bashir G Chouaib S . Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin. Immunol.130 (1), 89–97 (2009).
   PubMed Web of Science ®Google Scholar
• Ganai S Arenas RB Forbes NS . Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br. J. Cancer101 (10), 1683–1691 (2009).
   PubMed Web of Science ®Google Scholar
• Loeffler M Le'negrate G Krajewska M Reed JC . Inhibition of tumor growth using Salmonella expressing Fas ligand. J. Natl Cancer Inst.100 (15), 1113–1116 (2008).
   PubMedGoogle Scholar
• Theys J Landuyt W Nuyts S et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther.8 (4), 294–297 (2001).
   PubMed Web of Science ®Google Scholar
• Theys J Pennington O Dubois L et al. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br. J. Cancer95 (9), 1212–1219 (2006).
   PubMed Web of Science ®Google Scholar
• King I Bermudes D Lin S et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Human Gene Ther.13 (10), 1225–1233 (2002).
   PubMed Web of Science ®Google Scholar
• Chen G Tang B Yang B et al. Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model. Appl. Microbiol. Biotechnol.97 (10), 4393–4401 (2013).
   PubMed Web of Science ®Google Scholar
• Dai YM Toley BJ Swofford CA Forbes NS . Construction of an inducible cell-communication system that amplifies Salmonella gene expression in tumor tissue. Biotechnol. Bioengin.110 (6), 1769–1781 (2013).
   PubMed Web of Science ®Google Scholar
• Nuyts S Theys J Landuyt W Van Mellaert L Lambin P Anne J . Increasing specificity of anti-tumor therapy: cytotoxic protein delivery by non-pathogenic clostridia under regulation of radio-induced promoters. Anticancer Res.21 (2A), 857–861 (2001).
   PubMed Web of Science ®Google Scholar
• Nuyts S Van Mellaert L Barbe S et al. Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters. Appl. Environ. Microbiol.67 (10), 4464–4470 (2001).
   PubMed Web of Science ®Google Scholar
• Nuyts S Van Mellaert L Theys J et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation. Gene Ther.8 (15), 1197–1201 (2001).
   PubMed Web of Science ®Google Scholar
• Jeong JH Kim K Lim D et al. Anti-tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium. PLoS One9 (1), e80050 (2014).
   PubMed Web of Science ®Google Scholar
• Nauts HC Swift WE Coley BL . The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, MD, reviewed in the light of modern research. Cancer Res.6 (4), 205–216 (1946).
   PubMed Web of Science ®Google Scholar
• Mccarthy EF . The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J.26, 154–158 (2006).
   PubMedGoogle Scholar
• Richardson MA Ramirez T Russell NC Moye LA . Coley toxins immunotherapy: a retrospective review. Altern. Ther. Health Med.5 (3), 42–47 (1999).
   PubMed Web of Science ®Google Scholar
• Forbes NS . Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer10 (11), 785–794 (2010).
   PubMed Web of Science ®Google Scholar
• Kohwi Y Imai K Tamura Z Hashimoto Y . Antitumor effect of Bifidobacterium infantis in mice. Gan.69 (5), 613–618 (1978).
   PubMedGoogle Scholar
• Malmgren RA Flanigan CC . Localization of the vegetative form of Clostridium tetani in mouse tumor following intravenous spore administration. Cancer Res.15 (7), 473–478 (1955).
   PubMed Web of Science ®Google Scholar
• Pawelek JM Low KB Bermudes D . Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res.57 (20), 4537–4544 (1997).
   PubMed Web of Science ®Google Scholar
• Kim SH Castro F Paterson Y Gravekamp C . High efficacy of a listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res.69 (14), 5860–5866 (2009).
   PubMed Web of Science ®Google Scholar
• Lambin P Theys J Landuyt W et al. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. Anaerobe4 (4), 183–188 (1998).
   PubMed Web of Science ®Google Scholar
• Kimura NT Taniguchi S Aoki K Baba T . Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res.40 (6), 2061–2068 (1980).
   PubMed Web of Science ®Google Scholar
• Yazawa K Fujimori M Amano J Kano Y Taniguchi S . Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther.7 (2), 269–274 (2000).
   PubMed Web of Science ®Google Scholar
• Dang LH Bettegowda C Huso DL Kinzler KW Vogelstein B . Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl Acad. Sci. USA98 (26), 15155–15160 (2001).
   PubMed Web of Science ®Google Scholar
• Bettegowda C Dang LH Abrams R et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc. Natl Acad. Sci. USA100 (25), 15083–15088 (2003).
   PubMed Web of Science ®Google Scholar
• Hayashi K Zhao M Yamauchi K et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J. Cell. Biochem.106 (6), 992–998 (2009).
   PubMed Web of Science ®Google Scholar
• Hayashi K Zhao M Yamauchi K et al. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle8 (6), 870–875 (2009).
   PubMed Web of Science ®Google Scholar
• Yu YA Shabahang S Timiryasova TM et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol.22 (3), 313–320 (2004).
   PubMed Web of Science ®Google Scholar
• Westphal K Leschner S Jablonska J Loessner H Weiss S . Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res.68 (8), 2952–2960 (2008).
   PubMed Web of Science ®Google Scholar
• Ganai S Arenas RB Sauer JP Bentley B Forbes NS . Attenuated Salmonella typhimurium effectively targets breast cancer metastases. Ann. Surg. Oncol.16, 18–19 (2009).
   Web of Science ®Google Scholar
• Leschner S Westphal K Dietrich N et al. Tumor invasion of Salmonella enterica serovar typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha. PloS One4, e6692 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang M Swofford CA Forbes NS . Lipid A controls the robustness of intratumoral accumulation of attenuated Salmonella in mice. Int. J. Cancer135 (3), 647–657 (2014).
   PubMed Web of Science ®Google Scholar
• Kasinskas RW Forbes NS . Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res.67, 3201–3209 (2007).
   PubMed Web of Science ®Google Scholar
• Clairmont C Lee KC Pike J et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J. Infect. Dis.181 (6), 1996–2002 (2000).
   PubMed Web of Science ®Google Scholar
• Igney FH Krammer PH . Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol.71 (6), 907–920 (2002).
   PubMed Web of Science ®Google Scholar
• Zhao M Yang M Li X-M et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc. Natl Acad. Sci. USA102, 755–760 (2005).
   PubMed Web of Science ®Google Scholar
• Low KB Ittensohn M Luo X et al. Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans. Methods Mol. Med.90, 47–60 (2004).
   PubMedGoogle Scholar
• Zhao M Yang M Ma H et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res.66, 7647–7652 (2006).
   PubMed Web of Science ®Google Scholar
• Avogadri F Martinoli C Petrovska L et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res.65 (9), 3920–3927 (2005).
   PubMed Web of Science ®Google Scholar
• Lee CH Hsieh JL Wu CL Hsu HC Shiau AL . B cells are required for tumor-targeting Salmonella in host. Appl. Microbiol. Biotechnol.92 (6), 1251–1260 (2011).
   PubMed Web of Science ®Google Scholar
• Lee CH Hsieh JL Wu CL Hsu PY Shiau AL . T cell augments the antitumor activity of tumor-targeting Salmonella. Appl. Microbiol. Biotechnol.90 (4), 1381–1388 (2011).
   PubMed Web of Science ®Google Scholar
• Thamm DH Kurzman ID King I et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin. Cancer Res.11 (13), 4827–4834 (2005).
   PubMed Web of Science ®Google Scholar
• Yam C Zhao M Hayashi K Ma H et al. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J. Surg. Res.164 (2), 248–255 (2010).
   PubMed Web of Science ®Google Scholar
• Momiyama M Zhao M Kimura H et al. Inhibition and eradication of human glioma with tumor-targeting Salmonella typhimurium in an orthotopic nude-mouse model. Cell Cycle11 (3), 628–632 (2012).
   PubMed Web of Science ®Google Scholar
• Elson G Dunn-Siegrist I Daubeuf B Pugin J . Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood109 (4), 1574–1583 (2007).
   PubMed Web of Science ®Google Scholar
• Huang B Zhao J Shen S et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res.67 (9), 4346–4352 (2007).
   PubMed Web of Science ®Google Scholar
• Tye H Kennedy CL Najdovska M et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell22 (4), 466–478 (2012).
   PubMed Web of Science ®Google Scholar
• Kelly MG Alvero AB Chen R et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res.66 (7), 3859–3868 (2006).
   PubMed Web of Science ®Google Scholar
• Baneyx F Mujacic M . Recombinant protein folding and misfolding in Escherichia coli. Nat. Biotechnol.22 (11), 1399–1408 (2004).
   PubMed Web of Science ®Google Scholar
• Rocha EP Danchin A . An analysis of determinants of amino acids substitution rates in bacterial proteins. Mol. Biol. Evol.21 (1), 108–116 (2004).
   PubMed Web of Science ®Google Scholar
• Galán JE . Type III secretion machines: bacterial devices for protein delivery into host cells. Science284, 1322–1328 (1999).
   PubMed Web of Science ®Google Scholar
• Galan JE . Salmonella interactions with host cells: type III secretion at work. Annu. Rev. Cell. Dev. Biol.17, 53–86 (2001).
   PubMed Web of Science ®Google Scholar
• Samudrala R Heffron F Mcdermott JE . Accurate prediction of secreted substrates and identification of a conserved putative secretion signal for type III secretion systems. PLoS Pathog.5 (4), e1000375 (2009).
   PubMed Web of Science ®Google Scholar
• Sory MP Boland A Lambermont I Cornelis GR . Identification of the YopE and YopH domains required for secretion and internalization into the cytosol of macrophages, using the cyaA gene fusion approach. Proc. Natl Acad. Sci. USA92 (26), 11998–12002 (1995).
   PubMed Web of Science ®Google Scholar
• Bernhardt TG Roof WD Young R . Genetic evidence that the bacteriophage phi X174 lysis protein inhibits cell wall synthesis. Proc. Natl Acad. Sci. USA97 (8), 4297–4302 (2000).
   PubMed Web of Science ®Google Scholar
• Bernhardt TG Struck DK Young R . The lysis protein E of phi X174 is a specific inhibitor of the MraY-catalyzed step in peptidoglycan synthesis. J. Biol. Chem.276 (9), 6093–6097 (2001).
   PubMed Web of Science ®Google Scholar
• Witte A Wanner G Lubitz W Holtje JV . Effect of phi X174 protein E-mediated lysis on murein composition of Escherichia coli. FEMS Microbiol. Lett.164 (1), 149–157 (1998).
   PubMed Web of Science ®Google Scholar
• Stritzker J Weibel S Hill PJ Oelschlaeger TA Goebel W Szalay AA . Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int. J. Med. Microbiol.297 (3), 151–162 (2007).
   PubMed Web of Science ®Google Scholar
• Guzman LM Belin D Carson MJ Beckwith J . Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J. Bacteriol.177, 4121–4130 (1995).
   PubMed Web of Science ®Google Scholar
• Burns MR Wood SJ Miller KA Nguyen T Cromer JR David SA . Lysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants. Bioorg. Med. Chem.13 (7), 2523–2536 (2005).
   PubMed Web of Science ®Google Scholar
• Loessner H Endmann A Leschner S et al. Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo. Cell Microbiol.9 (6), 1529–1537 (2007).
   PubMed Web of Science ®Google Scholar
• Cronin CA Gluba W Scrable H . The lac operator-repressor system is functional in the mouse. Genes Dev.15 (12), 1506–1517 (2001).
   PubMed Web of Science ®Google Scholar
• Sutton MD Smith BT Godoy VG Walker GC . The SOS response: recent insights into umuDC-dependent mutagenesis and DNA damage tolerance. Annu. Rev. Genet.34, 479–497 (2000).
   PubMed Web of Science ®Google Scholar
• Miller MB Bassler BL . Quorum sensing in bacteria. Annu. Rev. Microbiol.55, 165–199 (2001).
   PubMed Web of Science ®Google Scholar
• Mengesha A Dubois L Lambin P et al. Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated Salmonella. Cancer Biol. Ther.5 (9), 1120–1128 (2006).
   PubMed Web of Science ®Google Scholar
• Chen J Yang B Cheng X et al. Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model. Cancer Sci.103 (2), 325–333 (2012).
   PubMed Web of Science ®Google Scholar
• Ryan RM Green J Williams PJ et al. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther.16 (3), 329–339 (2009).
   PubMed Web of Science ®Google Scholar
• Song LZ Hobaugh MR Shustak C Cheley S Bayley H Gouaux JE . Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science274 (5294), 1859–1866 (1996).
   PubMed Web of Science ®Google Scholar
• Vandana S Raje M Krishnasastry MV . The role of the amino terminus in the kinetics and assembly of alpha-hemolysin of Staphylococcus aureus. J. Biol. Chem.272 (40), 24858–24863 (1997).
   PubMed Web of Science ®Google Scholar
• Dinges MM Orwin PM Schlievert PM . Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev.13 (1), 16–34 (2000), table of contents.
   PubMed Web of Science ®Google Scholar
• Taylor BN Mehta RR Yamada T et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res.69 (2), 537–546 (2009).
   PubMed Web of Science ®Google Scholar
• Yamada T Hiraoka Y Das Gupta TK Chakrabarty AM . Regulation of mammalian cell growth and death by bacterial redox proteins: relevance to ecology and cancer therapy. Cell Cycle3 (6), 752–755 (2004).
   PubMed Web of Science ®Google Scholar
• Yamada T Goto M Punj V et al. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl Acad. Sci. USA99 (22), 14098–14103 (2002).
   PubMed Web of Science ®Google Scholar
• Yamada T Hiraoka Y Ikehata M et al. Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. Proc. Natl Acad. Sci. USA101 (14), 4770–4775 (2004).
   PubMed Web of Science ®Google Scholar
• Apiyo D Wittung-Stafshede P . Unique complex between bacterial azurin and tumor-suppressor protein p53. Biochem. Biophys. Res. Commun.332 (4), 965–968 (2005).
   PubMed Web of Science ®Google Scholar
• Chaudhari A Mahfouz M Fialho AM et al. Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancer growth. Biochemistry46 (7), 1799–1810 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki S Nakasato M Shibue T Koshima I Taniguchi T . Therapeutic potential of proapoptotic molecule Noxa in the selective elimination of tumor cells. Cancer Sci.100 (4), 759–769 (2009).
   PubMed Web of Science ®Google Scholar
• Seo YW Shin JN Ko KH et al. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J. Biol. Chem.278 (48), 48292–48299 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang L Lopez H George NM Liu X Pang X Luo X . Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ.18 (5), 864–873 (2011).
   PubMed Web of Science ®Google Scholar
• Seo YW Woo HN Piya S et al. The cell death-inducing activity of the peptide containing Noxa mitochondrial-targeting domain is associated with calcium release. Cancer Res.69 (21), 8356–8365 (2009).
   PubMed Web of Science ®Google Scholar
• Yagita H Takeda K Hayakawa Y Smyth MJ Okumura K . TRAIL and its receptors as targets for cancer therapy. Cancer Sci.95 (10), 777–783 (2004).
   PubMed Web of Science ®Google Scholar
• Kelley SK Harris LA Xie D et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther.299 (1), 31–38 (2001).
   PubMed Web of Science ®Google Scholar
• Leblanc HN Ashkenazi A . Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ.10 (1), 66–75 (2003).
   PubMed Web of Science ®Google Scholar
• Ogasawara J Watanabe-Fukunaga R Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature364 (6440), 806–809 (1993).
   PubMed Web of Science ®Google Scholar
• Rensing-Ehl A Frei K Flury R et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol.25 (8), 2253–2258 (1995).
   PubMed Web of Science ®Google Scholar
• Groot AJ Mengesha A Van Der Wall E Van Diest PJ Theys J Vooijs M . Functional antibodies produced by oncolytic clostridia. Biochem. Biophys. Res. Commun.364 (4), 985–989 (2007).
   PubMed Web of Science ®Google Scholar
• Agrawal N Bettegowda C Cheong I et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA101 (42), 15172–15177 (2004).
   PubMed Web of Science ®Google Scholar
• Osaki T Hashimoto W Gambotto A et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther.6 (5), 808–815 (1999).
   PubMed Web of Science ®Google Scholar
• Micallef MJ Tanimoto T Kohno K Ikeda M Kurimoto M . Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res.57 (20), 4557–4563 (1997).
   PubMed Web of Science ®Google Scholar
• Trinchieri G Matsumoto-Kobayashi M Clark SC Seehra J London L Perussia B . Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med.160 (4), 1147–1169 (1984).
   PubMed Web of Science ®Google Scholar
• Lanier LL Benike CJ Phillips JH Engleman EG . Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J. Immunol.134 (2), 794–801 (1985).
   PubMed Web of Science ®Google Scholar
• Phillips JH Gemlo BT Myers WW Rayner AA Lanier LL . In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J. Clin. Oncol.5 (12), 1933–1941 (1987).
   PubMed Web of Science ®Google Scholar
• Woldbaek PR Sande JB Stromme TA et al. Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice. Am. J. Physiol. Heart Circ. Physiol.289 (2), H708–714 (2005).
   PubMed Web of Science ®Google Scholar
• Shalmi CL Dutcher JP Feinfeld DA et al. Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion. J. Clin. Oncol.8 (11), 1839–1846 (1990).
   PubMed Web of Science ®Google Scholar
• Palmer DH Milner AE Kerr DJ Young LS . Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. Br. J. Cancer89 (5), 944–950 (2003).
   PubMed Web of Science ®Google Scholar
• Knox RJ Friedlos F Jarman M Roberts JJ . A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol.37 (24), 4661–4669 (1988).
   PubMed Web of Science ®Google Scholar
• Heap JT Theys J Ehsaan M Kubiak AM et al. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. Oncotarget5 (7), 1761–1769 (2014).
   PubMedGoogle Scholar
• Nemunaitis J Cunningham C Senzer N et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther.10 (10), 737–744 (2003).
   PubMed Web of Science ®Google Scholar
• Langemann T Koller VJ Muhammad A Kudela P Mayr UB Lubitz W . The Bacterial Ghost platform system: production and applications. Bioeng. Bugs1 (5), 326–336 (2010).
   PubMedGoogle Scholar
• Huter V Szostak MP Gampfer J et al. Bacterial ghosts as drug carrier and targeting vehicles. J. Control Release61 (1–2), 51–63 (1999).
   PubMed Web of Science ®Google Scholar
• Witte A Wanner G Blasi U Halfmann G Szostak M Lubitz W . Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J. Bacteriol.172 (7), 4109–4114 (1990).
   PubMed Web of Science ®Google Scholar
• Felnerova D Kudela P Bizik J et al. T cell-specific immune response induced by bacterial ghosts. Med. Sci. Monit.10 (10), BR362–370 (2004).
   PubMed Web of Science ®Google Scholar
• Paukner S Kohl G Lubitz W . Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J. Control Release94 (1), 63–74 (2004).
   PubMed Web of Science ®Google Scholar
• Macdiarmid JA Brahmbhatt H . Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Curr. Opin. Biotechnol.22 (6), 909–916 (2011).
   PubMed Web of Science ®Google Scholar
• Carleton HA Lara-Tejero M Liu X Galan JE . Engineering the type III secretion system in non-replicating bacterial minicells for antigen delivery. Nat. Commun.4, 1590 (2013).
   PubMed Web of Science ®Google Scholar
• Macdiarmid JA Mugridge NB Weiss JC et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell11 (5), 431–445 (2007).
   PubMed Web of Science ®Google Scholar
• Macdiarmid JA Amaro-Mugridge NB Madrid-Weiss J et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Biotechnol.27 (7), 643–651 (2009).
   PubMed Web of Science ®Google Scholar
• Chen DJ Osterrieder N Metzger SM et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl Acad. Sci. USA107 (7), 3099–3104 (2010).
   PubMed Web of Science ®Google Scholar
• Gujrati V Kim S Kim SH Min JJ Choy HE Kim SC Jon S . Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano8 (2), 1525–1537 (2014).
   PubMed Web of Science ®Google Scholar
• Zhao M Suetsugu A Ma HY et al. Efficacy against lung metastasis with a tumor-targeting mutant of Salmonella typhimurium in immunocompetent mice. Cell Cycle11 (1), 187–193 (2012).
   PubMed Web of Science ®Google Scholar